Short report
Subfoveal choroidal neovascularization in a 3-year-old child with North Carolina macular dystrophy

https://doi.org/10.1016/j.jaapos.2007.06.010Get rights and content

North Carolina macular dystrophy is characterized by nonprogressive atrophy of the choroid, choriocapillaris, and the retinal pigment epithelial layer.1, 2 The characteristic retinal findings, ranging from scattered drusen to a posterior staphyloma, have been reported as early as infancy and usually reach their greatest magnitude in the second decade of life.3 Herein, we describe a case of a 3-year-old boy with a documented family history of North Carolina macular dystrophy who presented with a subfoveal choroidal neovascular membrane in addition to the macular dystrophic changes.

Section snippets

Case Report

A 3-year-old boy with a history of a retinal dystrophy was referred to the pediatric ophthalmology clinic at the New England Eye Center for a pediatric ophthalmologic examination. The patient was a former 32-week-old, 1770 g, premature child whose father had a documented history of North Carolina macular dystrophy. The patient had been examined at 34 weeks of gestational age in the neonatal intensive care unit at another institution during a routine screening for retinopathy of prematurity.

Discussion

Lefler et al1 and Frank et al2 were the first to report a progressive, dominantly inherited foveal dystrophy that was characterized by good color vision and normal full-field electroretinogram and electro-oculogram responses. Other previously characterized dystrophies, including central areolar pigment epithelial dystrophy, are now thought to be part of North Carolina macular dystrophy.7

Through linkage analysis, North Carolina macular dystrophy has been localized to chromosome 6q14-q16.2;

Literature Search

A MEDLINE search covering the years 1950 to 2007 was performed using the search terms North Carolina Macular Dystrophy, autosomal dominant macular dystrophy, dominant progressive foveal dystrophy, dominant macular degeneration with aminoaciduria, Lefler Wadsworth Sidbury syndrome, and autosomal dominant pattern dystrophy, although North Carolina Macular Dystrophy was not described until 1974.

References (7)

There are more references available in the full text version of this article.

Cited by (16)

  • North Carolina macular dystrophy: A case report

    2019, Journal Francais d'Ophtalmologie
  • Thirty-year follow-up of an African American family with macular dystrophy of the retina, locus 1 (North Carolina Macular Dystrophy)

    2011, Ophthalmology
    Citation Excerpt :

    Given the small sample size, it is not possible to determine whether myopia is directly associated with MCDR1 or merely a spuriously observed trait within this pedigree. Furthermore, there is only 1 other report describing the refraction of an affected patient with MCDR1, a 3 year-old child who had a retinoscopic refraction of +1.00 diopters.16 Affected family members without CNV or amblyopia who were followed over the 30-year period did not experience a significant decline in VA, despite an increased amount of pigmentation seen within grade 3 lesions.

  • A Reappraisal of the Clinical Spectrum of North Carolina Macular Dystrophy

    2009, Ophthalmology
    Citation Excerpt :

    For instance, Small et al4 reported a 3-month-old boy with a grade 3 lesion. Rhee et al21 also described a 3-year-old boy with evidence of CNV who had macular atrophy diagnosed at 2 weeks of age (34 weeks gestational age). This obviously suggests that the clinical process can begin in utero, clearly in contrast to AMD.

  • Intravitreal bevacizumab for idiopathic choroidal neovascularization

    2009, Journal of AAPOS
    Citation Excerpt :

    Fluorescein angiography demonstrated late fluorescein staining of the fibrotic CNV, with no signs of progression (Figure 1E). To date, different treatment approaches for children with CNV have been described: observation, laser photocoagulation, submacular surgery, ocular photodynamic therapy with verteporfin, and intravitreal injections of antivascular endothelial growth factor (VEGF) agents.1-7 Several anti-VEGF agents are now being used intravitreally for CNV in adults.

  • A novel tandem duplication of PRDM13 in a Chinese family with North Carolina macular dystrophy

    2022, Graefe's Archive for Clinical and Experimental Ophthalmology
  • Macular Dystrophies

    2022, Albert and Jakobiec's Principles and Practice of Ophthalmology: Fourth Edition
View all citing articles on Scopus
View full text